youtube_live
Q3 2026 earnings • released • EPS beat +5.68% • Revenue beat +2.14%
See resultschevron_right
RVTY:NYSE
Revvity Inc
$153.84
arrow_downward
-3.56%(-5.68) 1D
Nov 5, 12:33:15 PM GMT-5 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for RVTY...
Open
$157.67
High
$158.78
Low
$153.74
Mkt. cap
17.79B
Avg. vol.
1.97M
Volume
638.26K
52-wk high
$171.74
52-wk low
$81.22
Beta
1.08
Shares outstanding
111.59M
No. of employees
11K
Open
$157.67
High
$158.78
Low
$153.74
Mkt. cap
17.79B
Avg. vol.
1.97M
Volume
638.26K
52-wk high
$171.74
52-wk low
$81.22
Beta
1.08
Shares outstanding
111.59M
No. of employees
11K
News stories
From web sources and news partners
Yahoo Finance
·
18 hours ago
Revvity, Inc. (RVTY) Stock Forecasts
GuruFocus
·
20 hours ago
RVTY Maintained by Barclays -- Price Target Raised to $175
Investing.com
·
1 day ago
Stifel raises Revvity stock price target to $177 on AI demand
Investing.com
·
1 day ago
BofA raises Revvity stock price target on strong Q3 results
Profile
Revvity, Inc. is a multinational company headquartered in Waltham, Massachusetts, USA, in the life sciences and diagnostics business that is focused on selling to the pharmaceutical and biotechnology industries, especially in relation to approaches making use of new cell therapy or gene therapy developments. Its origins lie with the long-existing company PerkinElmer, which has been in a variety of business lines.
In 2022, a split of PerkinElmer resulted in one part, comprising its applied, food and enterprise services businesses, being sold to the private equity firm New Mountain Capital for $2.45 billion and thus no longer being public but keeping the PerkinElmer name. The other part, comprising the life sciences and diagnostics businesses, remained public but required a new name, which in 2023 was announced as Revvity, Inc. From the perspective of Revvity, the goal of creating a separate company was that its businesses might show greater profit margins and more in the way of growth potential. An associated goal was to have more financial flexibility moving forward. On May 16, 2023, the PerkinElmer stock symbol PKI was replaced by the new symbol RVTY. Wikipedia
About Revvity Inc
CEOPrahlad Singh
Employees11K
Founded1947
HeadquartersWaltham, Massachusetts, United States
SectorHealth care
Industry-
Websiterevvity.com
Analyst ratings
Based on 15 analysts giving stock ratings to RVTY in the past 3 months
Buy
Buy
6
Hold
9
Sell
0
12-month forecast
Based on 15 Wall Street analysts offering 12 month price targets for RVTY in the last 3 months.
Highest
Current $153.84
$190.00 (+23.50%)
Average
$166.85 (+8.46%)
Lowest
$120.00 (-22.00%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Puneet Souda Leerink Partners | Buy | Maintained | $180.00 | +17% | 11/05/2026 |
Daniel Brennan TD Cowen | Buy | Maintained | $185.00 | +20.3% | 11/04/2026 |
Dan Leonard RBC Capital | Hold | Reiterated | $172.00 | +11.8% | 11/03/2026 |
Casey Woodring J.P. Morgan | Hold | Maintained | $160.00 | +4% | 11/04/2026 |
Daniel Arias Stifel Nicolaus | Hold | Reiterated | $177.00 | +15.1% | 11/04/2026 |
Catherine Ramsey Schulte Robert W. Baird | Buy | Maintained | $190.00 | +23.5% | 11/04/2026 |
Lu Li Bank of America Securities | Hold | Reiterated | $185.00 | +20.3% | 11/03/2026 |
Luke Sergott Barclays | Hold | Maintained | $175.00 | +13.8% | 11/04/2026 |
Vijay Kumar Evercore ISI | Buy | Maintained | $180.00 | +17% | 11/03/2026 |
Eve Burstein Bernstein | Hold | Reiterated | $120.00 | -22% | 10/19/2026 |
Michael Ryskin Bank of America Securities | Hold | Maintained | $165.00 | +7.3% | 10/09/2026 |
Matt Larew William Blair | Buy | Initiated | - | - | 10/05/2026 |
Evie Koslosky Goldman Sachs | Hold | Maintained | $140.00 | -9% | 09/20/2026 |
Unknown Analyst CFRA | Hold | Downgraded | - | - | 09/18/2026 |
Unknown Analyst UBS | Hold | Initiated | $140.00 | -9% | 09/08/2026 |
Doug Schenkel UBS | Hold | Downgraded | $140.00 | -9% | 09/09/2026 |
Paul Knight KeyBanc | Buy | Maintained | $165.00 | +7.3% | 09/04/2026 |
Unknown Analyst KeyBanc | Buy | Maintained | $165.00 | +7.3% | 09/04/2026 |
Evan Stampler Wells Fargo | Hold | Maintained | $110.00 | -28.5% | 08/05/2026 |
Unknown Analyst Wells Fargo | Hold | Maintained | $110.00 | -28.5% | 08/05/2026 |
Michael Polark Wolfe Research | Hold | Initiated | - | - | 06/01/2026 |
Unknown Analyst Guggenheim | Hold | Reiterated | - | - | 05/11/2026 |
Unknown Analyst Goldman Sachs | Hold | Maintained | $95.00 | -38.2% | 04/14/2026 |
Jack Meehan Nephron | Hold | Upgraded | $90.00 | -41.5% | 03/26/2026 |
Brandon Couillard Wells Fargo | Hold | Maintained | $110.00 | -28.5% | 02/03/2026 |
Tycho Peterson Jefferies | Hold | Maintained | $105.00 | -31.7% | 02/02/2026 |
Last report
Nov 3, 2026
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
$1.37 / $1.30
+5.68%beat
arrow_upward
Revenue / Est. (USD)
709.61M / 694.74M
+2.14%beat
arrow_upward
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Apr 2026 | Jul 2026 |
|---|---|---|---|---|
Revenue | 698.95M | 772.06M | 711.12M | 729.69M |
Cost of goods sold | 324.34M | 350.40M | 323.46M | 312.82M |
Cost of revenue | 324.34M | 350.40M | 323.46M | 312.82M |
Research and development expenses | 50.80M | 58.18M | 57.89M | 48.97M |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 227.44M | 208.55M | 241.91M | 243.46M |
Operating expense | 278.23M | 266.73M | 299.80M | 292.43M |
Total operating expenses | 602.58M | 617.12M | 623.26M | 605.25M |
Operating income | 96.37M | 154.93M | 87.86M | 124.44M |
Other non operating income | - | - | - | - |
EBT including unusual items | 55.68M | 91.56M | 49.99M | 63.53M |
EBT excluding unusual items | 76.49M | 133.38M | 65.92M | 105.36M |
Income tax expense | 8.46M | -4.21M | 9.10M | 10.05M |
Effective tax rate | 15.20% | -4.60% | 18.20% | 15.82% |
Other operating expenses | - | - | - | - |
Net income | 46.65M | 98.36M | 40.72M | 51.82M |
Net profit margin | 6.67% | 12.74% | 5.73% | 7.10% |
Earnings per share | 1.18 | 1.70 | 1.06 | 1.41 |
Interest and investment income | 6.92M | 5.75M | 6.30M | 5.26M |
Interest expense | -22.77M | -23.51M | -24.72M | -22.99M |
Net interest expenses | -15.85M | -17.76M | -18.41M | -17.73M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 198.43M | 258.01M | 192.91M | 226.47M |
Gain or loss from assets sale | - | - | -5.07M | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events